Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.CERC · Entity 4936 | Chief Business Officer | August 18, 2017 | August 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date August 18, 2017 · Filed August 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2027-08-18 | Direct | 25,000 |
Reported balance
After 2017-08-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-08-18 · Grant · Acquired 25,000 · Balance 25,000 F1: One third of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining two thirds of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 24 months beginning on 18-Aug-2017 F2: The stock options vest 1/3 at the first anniversary and 1/36th each month thereafter for the next two years. |
Filing footnotes · ownership attribution and instrument terms
F1: One third of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining two thirds of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 24 months beginning on 18-Aug-2017
F2: The stock options vest 1/3 at the first anniversary and 1/36th each month thereafter for the next two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2017 Filed Aug 22, 2017 14:01 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001562180-17-002780 · primarydocument.xml · derivative · entry 1 Kaiser John Joseph · CIK 0001429406 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-08-18 F1 · derivative.exercise_date: One third of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining two thirds of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 24 months beginning on 18-Aug-2017 F2 · derivative.exercise_date: The stock options vest 1/3 at the first anniversary and 1/36th each month thereafter for the next two years. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 22:06 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001562180-17-000408 · primarydocument.xml · derivative · entry 1 Kaiser John Joseph · CIK 0001429406 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: 8,333 of the shares underlying the option vested and became exercisable on the date of grant; 8,333 shares shall vest and become exercisable on the first anniversary of the date of grant, and 8,334 shares shall vest and become exercisable on the second anniversary of the date of grant, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.